UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 21 2012Proteonomix, Inc.

PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.

Michael Cohen, the Chief Executive Officer of the Company stated: "At least thirty (30) patients have been screened so far pursuant to inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol.  The initiation of screening is the first step towards commencement of the clinical trial of UMK-121."

Source:

Proteonomix, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Can psychedelics improve sexual functioning and satisfaction?
Reduction of prenatal depression associated with higher full-term birth rates
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions
Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
Mediterranean diet and exercise reshape gut microbiome, aiding weight loss
Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth
Resistant starch diet proves a game changer for weight loss and diabetes control

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Korean fermented food Doenjang shows promise in alleviating menopausal symptoms